Immune Deficiency, Common Variable (CVID)
Overview
Common Variable Immune Deficiency (CVID) is a primary immunodeficiency disorder characterized by markedly reduced levels of serum immunoglobulins (IgG, and often IgA and/or IgM) and an impaired ability to produce adequate antibody responses to infections and vaccines. It is called “common variable” because it is one of the most frequently diagnosed primary immunodeficiencies, yet its clinical presentation varies widely.
Who it affects: CVID can develop at any age, but most diagnoses occur in early adulthood (20‑40 years). Both sexes are affected equally, although some studies suggest a slight male predominance in certain ethnic groups.
Prevalence: Worldwide, CVID affects roughly 1 in 25,000–50,000 people, making it the most common clinically significant primary antibody deficiency (Mayo Clinic; Jeffrey et al., 2020). In the United States, an estimated 70,000–120,000 individuals live with CVID, though many remain undiagnosed.
Symptoms
Symptoms result from recurrent infections, chronic inflammation, and organ‑specific immune dysregulation. The spectrum is broad; patients may experience only a few symptoms or a complex multi‑system disease.
Infectious manifestations
- Upper respiratory infections: frequent sinusitis, otitis media, pharyngitis, and laryngitis.
- Lower respiratory infections: bronchitis, recurrent pneumonia, bronchiectasis, and chronic cough.
- Gastrointestinal infections: persistent diarrhea, giardiasis, and infections with Campylobacter or Salmonella.
- Ear, nose, and throat (ENT) complications: chronic otitis media with effusion, nasal polyps.
- Skin infections: cellulitis, impetigo, or chronic warts.
Non‑infectious / Autoimmune manifestations
- Autoimmune cytopenias: autoimmune hemolytic anemia, immune thrombocytopenia, neutropenia.
- Autoimmune endocrine disease: hypothyroidism, type 1 diabetes, adrenal insufficiency.
- Gastrointestinal inflammation: inflammatory bowel‑like disease, granulomatous colitis, celiac‑type sprue.
- Lymphoproliferative disease: enlarged lymph nodes, splenomegaly, or persistent granulomas.
- Pulmonary complications: interstitial lung disease (GLILD – granulomatous‑lymphocytic interstitial lung disease).
- Neurologic involvement: peripheral neuropathy, ataxia, or autoimmune encephalitis (rare).
Other common features
- Chronic fatigue and malaise.
- Unexplained weight loss.
- Growth retardation in children.
- Family history of primary immunodeficiency (≈15 % of cases).
Causes and Risk Factors
In most patients, CVID is considered idiopathic, meaning the exact cause is unknown. However, several mechanisms have been identified:
Genetic factors
- Mutations in genes that regulate B‑cell development and function (e.g., TNFRSF13B (TACI), ICOS, CD19, BAFF‑R, NFKB1, NFKB2).
- Monogenic forms account for ~10‑20 % of CVID cases; most are polygenic with complex inheritance.
Environmental triggers
- Viral infections (especially early‑life Epstein‑Barr virus) may unmask an underlying immune defect.
- Exposure to certain toxins or chronic inflammation could contribute to disease progression.
Risk factors
- Family history of primary immunodeficiency or autoimmune disease.
- Being of European descent (higher reported prevalence in Caucasian populations).
- History of recurrent, severe infections in childhood or adolescence.
Diagnosis
Diagnosis requires a combination of clinical suspicion, laboratory evaluation, and exclusion of secondary causes (e.g., medications, HIV, malignancy).
Key diagnostic criteria (per European Society for Immunodeficiencies and American Academy of Allergy, Asthma & Immunology)
- Markedly reduced serum IgG (often < 4 g/L) with low IgA and/or IgM.
- Failure to mount adequate specific antibody responses to protein and polysaccharide vaccines.
- Onset of symptoms after age 2 years.
- Exclusion of other defined causes of hypogammaglobulinemia.
Laboratory tests
- Serum immunoglobulin quantitation: IgG, IgA, IgM.
- Specific antibody titers: pre‑ and post‑vaccination responses to tetanus, diphtheria, pneumococcus, and Haemophilus influenzae type b.
- Complete blood count (CBC) with differential: to detect cytopenias.
- Lymphocyte phenotyping (flow cytometry): evaluates B‑cell subsets (e.g., low switched memory B cells).
- Genetic testing: targeted gene panels or whole‑exome sequencing when a monogenic cause is suspected.
Imaging & other studies
- Chest X‑ray or high‑resolution CT scan to assess for bronchiectasis, interstitial lung disease, or lymphoid hyperplasia.
- Abdominal ultrasound for splenomegaly.
- Endoscopy with biopsy if chronic diarrhea or GI inflammation is present.
Treatment Options
Therapy focuses on infection prevention, correction of antibody deficiency, and management of autoimmune/inflammatory complications.
Immunoglobulin replacement therapy (IGRT)
- Intravenous immunoglobulin (IVIG): administered every 3‑4 weeks; dose 400–600 mg/kg.
- Subcutaneous immunoglobulin (SCIG):** weekly or bi‑weekly injections; offers more stable serum IgG levels and greater flexibility.
- IGRT reduces serious bacterial infections by ~70‑80 % and improves quality of life (Cleveland Clinic, 2022).
Antibiotic strategies
- Short courses for acute infections (e.g., amoxicillin‑clavulanate for sinusitis).
- Prophylactic antibiotics (e.g., trimethoprim‑sulfamethoxazole) in patients with recurrent sinopulmonary infections or bronchiectasis.
Management of autoimmune/ inflammatory disease
- Corticosteroids: for acute flares of cytopenias or organ‑specific inflammation.
- Steroid‑sparing agents: azathioprine, mycophenolate mofetil, rituximab (especially for immune thrombocytopenia or GLILD).
- Biologic therapies: TNF‑α inhibitors or IL‑6 blockers in refractory cases, guided by specialist input.
Supportive care
- Vaccination with inactivated vaccines (influenza, pneumococcal, COVID‑19). Live vaccines are contraindicated.
- Pulmonary hygiene: airway clearance techniques, bronchodilators, and mucolytics for bronchiectasis.
- Nutrition optimization: high‑protein diet, vitamin D and calcium supplementation if steroids are used.
Living with Immune Deficiency, Common Variable
Effective self‑management can dramatically reduce infection frequency and improve overall well‑being.
Practical daily tips
- Adhere to IGRT schedule: set reminders; keep a log of infusion dates and any side effects.
- Hand hygiene and respiratory etiquette: wash hands ≥20 seconds, use alcohol‑based sanitizer, cover coughs.
- Avoid high‑risk exposures: crowded indoor events during peak respiratory virus season, especially if not fully vaccinated.
- Stay current with vaccines: work with your immunologist to schedule inactivated vaccines annually.
- Monitor lung health: perform daily breathing exercises, use a home spirometer if recommended, and report new wheeze or sputum changes.
- Maintain an infection diary: note symptoms, temperature, and any antibiotics used; share with your care team.
- Psychosocial support: join patient advocacy groups (e.g., Immune Deficiency Foundation) for peer support.
Regular follow‑up
- Every 3–6 months: CBC, serum IgG levels, and assessment of infection burden.
- Annually: chest CT (if lung disease was present) and pulmonary function testing.
- Whenever new autoimmune symptoms appear: prompt referral to rheumatology or gastroenterology.
Prevention
While CVID itself cannot be prevented, many complications are avoidable.
- Vaccination: annual influenza, COVID‑19 booster, pneumococcal PCV13 followed by PPSV23 (as per CDC schedule).
- Prophylactic antibiotics: discussed with your physician if you have chronic lung disease.
- Environmental hygiene: keep home environments free of mold, dust, and pet dander that may trigger respiratory irritation.
- Travel precautions: avoid regions with endemic live‑vaccine requirements (e.g., yellow fever) unless an alternative plan is arranged.
Complications
If untreated or poorly controlled, CVID can lead to serious health problems.
- Chronic lung disease: bronchiectasis and GLILD can cause progressive respiratory failure.
- Gastrointestinal malabsorption: chronic diarrhea may lead to nutritional deficiencies and weight loss.
- Autoimmune cytopenias: severe anemia or thrombocytopenia may require transfusion.
- Lymphoma and other malignancies: increased risk (approximately 4–5 % lifetime risk) of non‑Hodgkin lymphoma and gastric cancer.
- Organ damage: splenomegaly, hepatic granulomas, or renal involvement.
- Psychological impact: chronic illness can contribute to anxiety, depression, and reduced quality of life.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden high fever (≥ 38.5 °C / 101.3 °F) that does not improve with antipyretics.
- Severe shortness of breath, chest pain, or wheezing that worsens rapidly.
- Rapidly spreading skin infection (redness, swelling, heat) with fever – possible sepsis.
- Sudden severe abdominal pain, vomiting, or bloody diarrhea.
- Signs of uncontrolled bleeding (e.g., nosebleed lasting > 20 minutes, gum bleeding, easy bruising).
- Unexplained sudden weakness, numbness, vision changes, or difficulty speaking – possible neurologic emergency.
- Persistent vomiting or inability to keep fluids down for > 24 hours.
These symptoms may indicate a life‑threatening infection, sepsis, severe autoimmune flare, or organ failure. Prompt medical evaluation can be lifesaving.
References
- Mayo Clinic. “Common Variable Immunodeficiency (CVID).” www.mayoclinic.org. Accessed June 2026.
- Jeffrey, D., et al. “Epidemiology of Primary Immunodeficiency in the United States.” Journal of Clinical Immunology, 2020; 40(5): 617‑627.
- Cleveland Clinic. “Immunoglobulin Replacement Therapy.” www.clevelandclinic.org. Updated 2022.
- Centers for Disease Control and Prevention. “Vaccines for Primary Immunodeficiency.” www.cdc.gov. Accessed June 2026.
- National Institutes of Health, NIAID. “Primary Immunodeficiency Diseases.” www.niaid.nih.gov. 2023.
- World Health Organization. “Management of Primary Immunodeficiency Disorders.” WHO Technical Report Series, 2021.